Results 231 to 240 of about 77,609 (253)

Ribavirin

2009
Jim Bellows, Robert Harrison, William Charney, Kevin Corkery, Lee Wugofski   +4 more
openaire   +2 more sources

Modelling how ribavirin improves interferon response rates in hepatitis C virus infection

Nature, 2004
Narendra M Dixit, Alan S Perelson
exaly  

Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID‐19

Journal of Medical Virology, 2020
Jahan S Khalili
exaly  

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

Lancet, The, 2014
Michael Manns, Maria Buti, Ewa Janczewska   +2 more
exaly  

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence

Hepatology, 2016
Eugene R Schiff, John M Vierling, Charles S Landis   +2 more
exaly  

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection

New England Journal of Medicine, 2002
Michael W Fried, K Rajender Reddy, Dieter Häussinger   +2 more
exaly  

Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study

Lancet Infectious Diseases, The, 2014
Ali S Omrani, Kamran Baig, Ziad Ahmed Memish   +2 more
exaly  

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort

Gut, 2016
Kerstin Herzer, Peter Ferenci, Michael Gschwantler   +2 more
exaly  

Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA

Proceedings of the National Academy of Sciences of the United States of America, 2018
François Ferron, Lorenzo Subissi, Etienne Decroly   +2 more
exaly  

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+)

Hepatology, 2016
Peter Angus, Gregory J Dore, Stanislas Pol   +2 more
exaly